337 results on '"Kilpatrick, Trevor"'
Search Results
2. Antigen-specific immunotherapy via delivery of tolerogenic dendritic cells for multiple sclerosis
3. Mertk-expressing microglia influence oligodendrogenesis and myelin modelling in the CNS
4. Parity is associated with long-term differences in DNA methylation at genes related to neural plasticity in multiple sclerosis
5. Mouse microglia express unique miRNA-mRNA networks to facilitate age-specific functions in the developing central nervous system
6. High-efficiency pharmacogenetic ablation of oligodendrocyte progenitor cells in the adult mouse CNS
7. White matter tract conductivity is resistant to wide variations in paranodal structure and myelin thickness accompanying the loss of Tyro3: an experimental and simulated analysis
8. The therapeutic effect of GAS6 in remyelination is dependent upon Tyro3.
9. Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.
10. Development of [18F]MIPS15692, a radiotracer with in vitro proof-of-concept for the imaging of MER tyrosine kinase (MERTK) in neuroinflammatory disease
11. Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study
12. Evidence for decreased copper associated with demyelination in the corpus callosum of cuprizone-treated mice
13. Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome
14. The Tolerogenic Influence of Dexamethasone on Dendritic Cells Is Accompanied by the Induction of Efferocytosis, Promoted by MERTK
15. The oligodendrocyte-enriched orphan G protein-coupled receptor Gpr62 is dispensable for central nervous system myelination
16. The clinical profile of NMOSD in Australia and New Zealand
17. Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome.
18. HLA-DRB1*15:01 and the MERTK Gene Interact to Selectively Influence the Profile of MERTK-Expressing Monocytes in Both Health and MS.
19. Patient‐determined disease steps is not interchangeable with the Expanded Disease Status Scale in mild to moderate multiple sclerosis
20. Multiple Sclerosis: Basic and Clinical
21. Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis
22. A pro-inflammatory diet in people with multiple sclerosis is associated with an increased rate of relapse and increased FLAIR lesion volume on MRI in early multiple sclerosis: A prospective cohort study
23. The Patient‐Determined Disease Steps scale is not interchangeable with the Expanded Disease Status Scale in mild to moderate multiple sclerosis.
24. Changes in employment status over time in multiple sclerosis following a first episode of central nervous system demyelination, a Markov multistate model study.
25. Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
26. DNA methylation signatures of Multiple Sclerosis occur independently of genetic risk and are primarily attributed to B cells and monocytes
27. Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity
28. Risk of a first clinical diagnosis of central nervous system demyelination in relation to human herpesviruses in the context of Epstein–Barr virus.
29. DNA Methylation Signatures of Multiple Sclerosis Occur Independently of Known Genetic Risk and Are Primarily Attributed to B Cells and Monocytes.
30. Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity
31. Comparative effectiveness of autologous hematopoietic stem cell transplant vs Fingolimod, Natalizumab, and Ocrelizumab in highly active relapsing-remitting multiple sclerosis
32. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies
33. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations
34. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy
35. Early predictors of visual and axonal outcomes after acute optic neuritis
36. 2326 Differential methylation mediates significant proportions of environmental and lifestyle factors’ associations with MS risk: results from the Ausimmune case-control study
37. 2413 Does serum neurofilament light chain level contribute to the prediction of treatment response in multiple sclerosis?
38. 2367 Developing tolerogenic dendritic cells as immunotherapy for multiple sclerosis
39. Achievements and obstacles of remyelinating therapies in multiple sclerosis
40. Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity.
41. Higher consumption of ultra-processed foods and increased likelihood of central nervous system demyelination in a case-control study of Australian adults.
42. Dysequilibrium of the PTH-FGF23-vitamin D axis in relapsing remitting multiple sclerosis; a longitudinal study
43. Cladribine Treatment for MS Preserves the Differentiative Capacity of Subsequently Generated Monocytes, Whereas Its Administration In Vitro Acutely Influences Monocyte Differentiation but Not Microglial Activation
44. Clinical impact of whole-genome sequencing in patients with early-onset dementia
45. Mouse microglia express unique miRNA-mRNA networks to facilitate age-specific functions in the developing central nervous system
46. Impact of telehealth on health care in a multiple sclerosis outpatient clinic during the COVID-19 pandemic
47. Gait stability reflects motor tracts damage at early stages of multiple sclerosis
48. Long-term trajectories of employment status, workhours and disability support pension status, after a first episode of CNS demyelination
49. A Functional and Neuropathological Testing Paradigm Reveals New Disability-Based Parameters and Histological Features for P0180–190-Induced Experimental Autoimmune Neuritis in C57BL/6 Mice
50. Axonally derived matrilin-2 induces proinflammatory responses that exacerbate autoimmune neuroinflammation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.